News Releases

RICHMOND, Va. & PETAH TIKVA, Israel, Oct 21, 2004 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ: INSM) and Fox Pharma announced today that Tzamal Pharma, a leading pharmaceutical sales and...

RICHMOND, Va. & SAN FRANCISCO, Oct 19, 2004 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ: INSM) today reported that the Company will begin clinical development of a small molecule tyrosine...

RICHMOND, Va., Sep 13, 2004 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ: INSM) today reported on results from a nine-month analysis of therapy with SomatoKine(R) (rhIGF-I/rhIGFBP-3 (mecasermin...

RICHMOND, Va., Sep 8, 2004 (BUSINESS WIRE) -- Insmed, Inc. (NASDAQ: INSM) announced today the initiation of a Phase I clinical study for the company's novel anti-tumor agent, recombinant human...

RICHMOND, Va., Aug 17, 2004 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) today announced that it has contacted the Berlin-Bremen Stock Exchange and requested an immediate halt to trading...

RICHMOND, Va., Jul 28, 2004 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM), a developer of pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical...

RICHMOND, Va., Jul 21, 2004 (BUSINESS WIRE) -- Insmed (NASDAQ: INSM) announced today that it will release second quarter financial results Wednesday, July 28, before market opens. The Company will...

RICHMOND, Va., Jul 20, 2004 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) today provided an update on the Company's ongoing pivotal Phase III clinical trial evaluating SomatoKine(R)...

RICHMOND, Va., Jul 12, 2004 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM) today announced the French authorities have authorized the use of and reimbursement for SomatoKine(R)...

RICHMOND, Va., Jul 19, 2004 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ: INSM) today announced that two independent studies were recently presented to the National Cancer Institutes 12th Annual...